Sinopharm Group Co. Ltd. (Sinopharm) has called its 2025 Annual General Meeting (AGM) for 9:00 a.m. on Thursday, 18 June 2026, at the company’s Shanghai headquarters (Meeting Room 1401, Sinopharm Group Building, No. 385 East Longhua Road, Huangpu District).
Key items slated for shareholder approval include:
1. 2025 Results & Governance Reports • Board and Supervisory Committee reports, alongside the audited consolidated financial statements for the year ended 31 December 2025, will be presented for endorsement.
2. Profit Distribution & Dividend • A final dividend of RMB0.69 per share (tax inclusive) for FY 2025. • Subject to approval, the dividend will be paid on or before 18 August 2026 to shareholders on record as of 30 June 2026. • The share register will be closed 25–30 June 2026 to determine dividend entitlements.
3. Director and Supervisor Remuneration • Authorisation for the Board and Supervisory Committee to set remuneration for directors and supervisors, respectively, for FY 2026.
4. Auditor Appointments • Re-appointment of Confucius International CPA Limited (international auditor) and Pan-China Certified Public Accountants LLP (domestic auditor) until the next AGM, with fees to be fixed by the Audit Committee.
5. Financial Guarantees • Delegation to the Board to provide guarantees for subsidiaries up to 30% of the company’s latest audited total assets over any rolling 12-month period, subject to Hong Kong Listing Rules compliance.
6. Capital Management Mandates • General mandate permitting the Board to issue Domestic and/or H Shares—individually or concurrently—up to 20% of each class’s existing issued share capital (excluding treasury shares) during the mandate period. • Special mandate authorising repurchase of up to 10% of H Shares in issue (excluding treasury shares) within the mandate period, with flexibility to cancel or hold repurchased shares as treasury stock and adjust the Articles of Association accordingly.
7. Debt Financing • Proposal to extend the validity period of the company’s non-financial corporate debt financing instruments registration.
Shareholders’ Schedule • AGM entitlement record date: 15 June 2026; share transfer registration for H-shareholders closes 12 June 2026 at 4:30 p.m. • Final-dividend record date: 30 June 2026; share transfer registration for H-shareholders closes 24 June 2026 at 4:30 p.m.
Procedures Eligible shareholders may appoint proxies; completed proxy forms must reach Computershare Hong Kong Investor Services (for H shares) or the company’s PRC office (for domestic shares) at least 24 hours before the AGM. The meeting is expected to conclude within half a day; attendees will bear their own travel and accommodation costs.
Board Composition As of 28 May 2026, Sinopharm’s Board comprises two executive directors (Lian Wanyong, Yang Binghua), nine non-executive directors and five independent non-executive directors, chaired by Jin Bin.
Comments